TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men
Brief Summary: The objective of the study is to assess the effect of the testosterone therapy on the body composition, lipid and glucose metabolism, inflammatory markers in patients with metabolic syndrome and hypogonadism.


Options:
A: Arm Label: Testosterone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone Gel (Androgel) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Testosterone Gel (Androgel); Assigned to Arm(s): Testosterone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Active Testosterone Gel; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate (open label), Drug: Testosterone gel | Arm Label: Placebo Gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sildenafil citrate (open label), Other: Placebo gel | Intervention Type: DRUG; Name: Sildenafil citrate (open label); Assigned to Arm(s): Active Testosterone Gel, Placebo Gel | Intervention Type: DRUG; Name: Testosterone gel; Assigned to Arm(s): Active Testosterone Gel | Intervention Type: OTHER; Name: Placebo gel; Assigned to Arm(s): Placebo Gel
C: Arm Label: Testosterone plus Lifestyle Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Testosterone, Other: Lifestyle Therapy | Arm Label: Placebo plus Lifestyle Therapy; Type: PLACEBO_COMPARATOR; Interventions: Other: Lifestyle Therapy, Drug: Placebo | Intervention Type: DRUG; Name: Testosterone; Assigned to Arm(s): Testosterone plus Lifestyle Therapy | Intervention Type: OTHER; Name: Lifestyle Therapy; Assigned to Arm(s): Placebo plus Lifestyle Therapy, Testosterone plus Lifestyle Therapy | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Lifestyle Therapy
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nebido (testosterone undecanoate) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nebido (testosterone undecanoate); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Systems of Support to Increase Colon Cancer Screening and Follow-up
Brief Summary: SOS is a four-arm randomized controlled study of ways to increase screening for colorectal cancer. About 40-50% of the people age 50 and older are not up to date on screening. This is a very important problem because screening both prevents colorectal cancer and decreases colon cancer deaths.

We are studying 3 different levels of support to help people get screened and follow-up after positive screening tests. These involve comparing to usual care stepwise increasing in intensity approaches; an automated approach of mailing information and home screening tests, this plus phone assistance by a medical assistant, both of these plus phone counseling and care management. We will also compare nurse assisted follow-up after a positive screening test compared to usual care

By doing this study we hope to increase colon cancer screening rates, and also follow-up rates for positive screening tests.


Options:
A: Arm Label: Arm 1 Physical Activity counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Counseling | Arm Label: Arm 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical Activity Counseling; Assigned to Arm(s): Arm 1 Physical Activity counseling
B: Arm Label: 1- Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 - Automated Mailing; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Mailing | Arm Label: 3 - Automated Mailing Plus Assisted; Type: EXPERIMENTAL; Interventions: Behavioral: Automated Mailing Plus Assisted | Arm Label: 4 - Auto Plus Assisted Plus Navigation; Type: EXPERIMENTAL; Interventions: Behavioral: Auto Plus Assisted Plus Navigation | Intervention Type: BEHAVIORAL; Name: Automated Mailing; Assigned to Arm(s): 2 - Automated Mailing | Intervention Type: BEHAVIORAL; Name: Automated Mailing Plus Assisted; Assigned to Arm(s): 3 - Automated Mailing Plus Assisted | Intervention Type: BEHAVIORAL; Name: Auto Plus Assisted Plus Navigation; Assigned to Arm(s): 4 - Auto Plus Assisted Plus Navigation
C: Intervention Type: BEHAVIORAL; Name: Mammography appointment reminders; telephone counseling; Assigned to Arm(s): N/A
D: Arm Label: Dexpramipexole; Type: EXPERIMENTAL; Interventions: Drug: Dexpramipexole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dexpramipexole; Assigned to Arm(s): Dexpramipexole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Repetitive Trans-cranial Magnetic Stimulation of the Motor Cortex in Fibromyalgia: A Prospective Randomized Blinded Placebo-controlled Study Evaluating the Clinical Efficiency and the Metabolic Correlate in 18FDG-PET
Brief Summary: Fibromyalgia (FM) syndrome is a chronic pain condition.Repetitive trans-cranial magnetic stimulation (rTMS) was thus suggested in this indication.


Options:
A: Arm Label: Active TMS; Type: ACTIVE_COMPARATOR; Interventions: Device: Active TMS | Arm Label: Sham TMS; Type: SHAM_COMPARATOR; Interventions: Device: Sham TMS | Intervention Type: DEVICE; Name: Active TMS; Assigned to Arm(s): Active TMS | Intervention Type: DEVICE; Name: Sham TMS; Assigned to Arm(s): Sham TMS
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Transcranial stimulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Transcranial stimulation | Intervention Type: OTHER; Name: Transcranial stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Transcranial stimulation; Assigned to Arm(s): 2
C: Arm Label: Active tDCS; Type: EXPERIMENTAL; Interventions: Device: Active tDCS | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Active tDCS | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS
D: Arm Label: Active tDCS and Active Mirror Therapy; Type: EXPERIMENTAL; Interventions: Device: transcranial Direct Current Stimulation (tDCS): active (Soterix ©), Behavioral: Mirror Therapy: active | Arm Label: Active tDCS and sham Mirror Therapy; Type: EXPERIMENTAL; Interventions: Device: transcranial Direct Current Stimulation (tDCS): active (Soterix ©), Behavioral: Mirror Therapy: Sham | Arm Label: Sham tDCS and active Mirror Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Mirror Therapy: active, Device: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©) | Arm Label: Sham tDCS and sham Mirrory Therapy; Type: SHAM_COMPARATOR; Interventions: Device: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©), Behavioral: Mirror Therapy: Sham | Intervention Type: DEVICE; Name: transcranial Direct Current Stimulation (tDCS): active (Soterix ©); Assigned to Arm(s): Active tDCS and Active Mirror Therapy, Active tDCS and sham Mirror Therapy | Intervention Type: BEHAVIORAL; Name: Mirror Therapy: active; Assigned to Arm(s): Active tDCS and Active Mirror Therapy, Sham tDCS and active Mirror Therapy | Intervention Type: DEVICE; Name: transcranial Direct Current Stimulation (tDCS): sham (Soterix ©); Assigned to Arm(s): Sham tDCS and active Mirror Therapy, Sham tDCS and sham Mirrory Therapy | Intervention Type: BEHAVIORAL; Name: Mirror Therapy: Sham; Assigned to Arm(s): Active tDCS and sham Mirror Therapy, Sham tDCS and sham Mirrory Therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Repetitive Trans-cranial Magnetic Stimulation of the Motor Cortex in Fibromyalgia: A Prospective Randomized Blinded Placebo-controlled Study Evaluating the Clinical Efficiency and the Metabolic Correlate in 18FDG-PET
Brief Summary: Fibromyalgia (FM) syndrome is a chronic pain condition.Repetitive trans-cranial magnetic stimulation (rTMS) was thus suggested in this indication.


Options:
A: Arm Label: Both Sham rTMS and Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham rTMS, Device: Sham Neuroacupuncture | Arm Label: Active rTMS and sham Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Active rTMS, Device: Sham Neuroacupuncture | Arm Label: Sham rTMS and Active Neuroacupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham rTMS, Device: Active Neuroacupuncture | Arm Label: Both Active rTMS and Neuroacupuncture; Type: ACTIVE_COMPARATOR; Interventions: Device: Active rTMS, Device: Active Neuroacupuncture | Intervention Type: DEVICE; Name: Active rTMS; Assigned to Arm(s): Active rTMS and sham Neuroacupuncture, Both Active rTMS and Neuroacupuncture | Intervention Type: DEVICE; Name: Sham rTMS; Assigned to Arm(s): Both Sham rTMS and Neuroacupuncture, Sham rTMS and Active Neuroacupuncture | Intervention Type: DEVICE; Name: Active Neuroacupuncture; Assigned to Arm(s): Both Active rTMS and Neuroacupuncture, Sham rTMS and Active Neuroacupuncture | Intervention Type: DEVICE; Name: Sham Neuroacupuncture; Assigned to Arm(s): Active rTMS and sham Neuroacupuncture, Both Sham rTMS and Neuroacupuncture
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Transcranial stimulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Transcranial stimulation | Intervention Type: OTHER; Name: Transcranial stimulation; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Transcranial stimulation; Assigned to Arm(s): 2
C: Arm Label: Active tDCS; Type: EXPERIMENTAL; Interventions: Device: Active tDCS | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: Active tDCS; Assigned to Arm(s): Active tDCS | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham tDCS
D: Arm Label: Group I; Type: ACTIVE_COMPARATOR; Interventions: Device: Real tDCS | Arm Label: Group II; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: Real tDCS; Assigned to Arm(s): Group I | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Group II

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Brief Summary: To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vyvanse (lisdexamfetamine dimesylate) | Intervention Type: DRUG; Name: Vyvanse (lisdexamfetamine dimesylate); Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A
C: Arm Label: Lisdexamfetamine Dimesylate (LDX, SPD489); Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX, SPD489) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Brief Summary: To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting


Options:
A: Arm Label: Lisdexamfetamine Dimesylate (LDX, SPD489); Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX, SPD489) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Adhansia XR; Type: EXPERIMENTAL; Interventions: Drug: Adhansia XR | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Adhansia XR; Assigned to Arm(s): Adhansia XR | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
C: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: open label PR OROS methylphenidate | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: double blind PR OROS methylphenidate | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: double blind placebo | Intervention Type: DRUG; Name: double blind placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: double blind PR OROS methylphenidate; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: open label PR OROS methylphenidate; Assigned to Arm(s): 001
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb Randomized, Double-Blind, Multicenter, Placebo-Controlled, Dose Optimization, Crossover, Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Brief Summary: To evaluate the efficacy of LDX compared to placebo in adults with ADHD in the adult workplace environment (AWE) setting


Options:
A: Intervention Type: DRUG; Name: NRP104; Assigned to Arm(s): N/A
B: Arm Label: Lisdexamfetamine Dimesylate (LDX, SPD489); Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX, SPD489) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Vyvanse (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate | Arm Label: Adderall XR (AXR); Type: EXPERIMENTAL; Interventions: Drug: Adderall XR (mixed salts amphetamine) | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate; Assigned to Arm(s): Vyvanse (LDX) | Intervention Type: DRUG; Name: Adderall XR (mixed salts amphetamine); Assigned to Arm(s): Adderall XR (AXR)
D: Arm Label: LDX Treatment; Type: EXPERIMENTAL; Interventions: Drug: LDX Treatment | Intervention Type: DRUG; Name: LDX Treatment; Assigned to Arm(s): LDX Treatment

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Thrice Weekly Intermittent Short Course Antituberculosis Chemotherapy in Tuberculosis Patients With and Without HIV Infection
Brief Summary: Tuberculosis (TB) is the most common opportunistic infection among HIV infected persons living in developing countries. Directly observed treatment, short-course (DOTS) is the internationally recommended strategy for the treatment of TB. However, the efficacy of DOTS for the treatment of HIV-associated TB is not well studied. This study aims to compare the efficacy of thrice weekly DOTS in HIV-infected versus HIV-negative patients with TB.


Options:
A: Arm Label: HIV infected; Type: EXPERIMENTAL; Interventions: Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | Arm Label: HIV negative; Type: ACTIVE_COMPARATOR; Interventions: Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | Intervention Type: DRUG; Name: INH, Rifampicin, Ethambutol and Pyrazinamide; Assigned to Arm(s): HIV infected | Intervention Type: DRUG; Name: INH, Rifampicin, Ethambutol and Pyrazinamide; Assigned to Arm(s): HIV negative
B: Arm Label: Delayed Start Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Delayed Start Linezolid | Arm Label: Immediate Start Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Immediate Start Linezolid | Intervention Type: DRUG; Name: Immediate Start Linezolid; Assigned to Arm(s): Immediate Start Linezolid | Intervention Type: DRUG; Name: Delayed Start Linezolid; Assigned to Arm(s): Delayed Start Linezolid
C: Arm Label: Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Moxifloxacin, Drug: Linezolid | Arm Label: Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Linezolid, Drug: Clofazimine | Arm Label: Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Linezolid | Arm Label: Control Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB. | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Pretomanid; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): Regimen 1 | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Clofazimine; Assigned to Arm(s): Regimen 2 | Intervention Type: DRUG; Name: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.; Assigned to Arm(s): Control Regimen
D: Arm Label: Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Linezolid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Hemodialysis Patients With Chronic Renal Anaemia
Brief Summary: This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous methoxy polyethylene glycolepoetin beta (Mircera) for the maintenance of hemoglobin levels in hemodialysis participants with chronic renal anemia. Participants currently receiving intravenous epoetin alfa or beta or darbepoetin alfa will receive intravenous Mircera at a starting dose of 120, 200 or 360 micrograms/month (based on the erythropoietin stimulating agent \[ESA\] dose administered on week -1). Subsequent doses will be adjusted to maintain hemoglobin levels within the target range of 10 to12 gram per deciliter (g/dL). The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.


Options:
A: Arm Label: C.E.R.A.; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Arm Label: Darbepoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Intervention Type: DRUG; Name: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals; Assigned to Arm(s): C.E.R.A., Darbepoetin
B: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
C: Arm Label: C.E.R.A.; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.) | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta (C.E.R.A.); Assigned to Arm(s): C.E.R.A.
D: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Oral Vitamin B12 Administration for Vitamin B12 Deficiency After Total Gastrectomy
Brief Summary: Pernicious anemia develops in 50% of total gastrectomized due to gastric cancer patients. Lack of intrinsic factor, which is secreted by parietal cell from stomach wall causes deficiency of cobalamin, which, in final, causes pernicious anemia. Thus, patients who had undergone total gastrectomy needs to be provided externally with cobalamin. Until now, intramuscular injection of cyanocobalamin has been the choice of treatment for cobalamin deficiency, but it has demerits in that it causes discomfort of coming to the hospital to get an injection, and in its high costs.

However, in pernicious anemia in old age and absorption disorder patients, it has been reported that oral administration of cobalamin had effect of elevating serum vitamin B12. Thus, this study was designed to prove the effect of oral administration of vitamin B12 in total gastrectomized patients with cobalamin deficiency.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mecobalamin | Intervention Type: DRUG; Name: mecobalamin; Assigned to Arm(s): 1
B: Arm Label: oral Cobalamin (vitamin B12); Type: EXPERIMENTAL; Interventions: Drug: oral Cobalamin (vitamin B12) | Arm Label: intramuscular Cobalamin (vitamin B12); Type: EXPERIMENTAL; Interventions: Drug: intramuscular Cobalamin (vitamin B12) | Intervention Type: DRUG; Name: oral Cobalamin (vitamin B12); Assigned to Arm(s): oral Cobalamin (vitamin B12) | Intervention Type: DRUG; Name: intramuscular Cobalamin (vitamin B12); Assigned to Arm(s): intramuscular Cobalamin (vitamin B12)
C: Intervention Type: DRUG; Name: Metformin on top of intensive insulin therapy; Assigned to Arm(s): N/A
D: Arm Label: i.m. injection of Vitamin B12; Type: ACTIVE_COMPARATOR; Interventions: Drug: i.m. injection of vitamin B12 | Arm Label: Oral administration of vitamin B12; Type: EXPERIMENTAL; Interventions: Drug: Oral administration of vitamin B12 | Intervention Type: DRUG; Name: Oral administration of vitamin B12; Assigned to Arm(s): Oral administration of vitamin B12 | Intervention Type: DRUG; Name: i.m. injection of vitamin B12; Assigned to Arm(s): i.m. injection of Vitamin B12

Answer: A